Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the launch in the United Kingdom of the first pre-filled, single-use disposable pen for the self-administration of Rebif®, the company's disease modifying drug (DMD) used to treat relapsing forms of multiple sclerosis (MS).
"At Merck Serono we are committed to making our products for patients as easy to use as possible to ensure they gain the maximum benefit from them. We are therefore proud to offer patients with MS the RebiDose device. It is the first and only injection delivery device that needs no assembly or priming by the patient. We believe the quick three-step injection process with RebiDose is an attractive option for an MS patient who is having trouble adhering to their current injectable MS therapy", said Andrew Paterson, Director of Neurology for Merck Serono.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1901